REGENXBIO Inc.
RGNXREGENXBIO Inc. (RGNX) is a biotechnology company specializing in the development and commercialization of gene therapy treatments. Founded in 2013, it focuses on leveraging its proprietary NAV Technology platform to create novel therapeutic options for a range of genetic, neurovascular, and retinal diseases. The company's goal is to advance gene therapy science and deliver transformative treatments to patients.
Company News
Kuehn Law is investigating whether officers and directors of Regenxbio, Inc. breached fiduciary duties by providing false or misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler Syndrome. The firm is seeking shareholders who purchased stock prior to February 9, 2022.
A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers thera...
DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Pha...
REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed ...
Pomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% o...
